Vhl Treatment: How It Works, Results and What to Expect

VHL treatment is individualized and may include regular surveillance, surgery or minimally invasive procedures, and targeted medication such as belzutifan. The aim is to treat tumors before they threaten organ function while avoiding unnecessary procedures whenever it is safe to do so.

VHL Treatment: How It Works and What to Expect

VHL treatment is based on active surveillance, targeted medicines and procedures chosen for the specific tumors a person has. Because von Hippel-Lindau syndrome can affect the kidneys, brain, spine, eyes, pancreas, adrenal glands and other areas, there is no single treatment plan for everyone.

The main goal is to prevent complications while preserving kidney function, vision, neurological function and quality of life. Small, stable tumors may be monitored closely, while growing, symptomatic or higher-risk tumors may need medication, surgery, ablation or other focused treatment.

A VHL review is usually performed by a multidisciplinary team. This helps connect imaging findings, laboratory testing, genetic information and symptoms so that each treatment decision considers the person’s overall health and future surveillance needs.

Understanding VHL and the Role of Lifelong Surveillance

Von Hippel-Lindau syndrome is a hereditary condition caused by a change in the VHL gene. It can lead to benign tumors, cysts and some cancerous tumors, most notably clear-cell renal cell carcinoma. Not everyone with VHL develops the same features, even within the same family.

Regular surveillance is an active part of VHL treatment, rather than simply waiting for symptoms. Depending on age, personal history and family history, monitoring can include eye examinations, brain and spinal MRI scans, abdominal imaging, blood pressure checks, hearing assessment and laboratory tests.

VHL test results should be interpreted in context. A genetic test may confirm a VHL gene variant, while imaging and eye examinations identify whether VHL-related changes are currently present. A genetic counselor can help patients and relatives understand what a result means for screening and family planning.

• Eye examinations can identify retinal lesions early.
• MRI can monitor the brain, spine, kidneys, pancreas and adrenal glands.
• Blood and urine tests may be used when a catecholamine-producing adrenal tumor is suspected.
• Follow-up intervals are individualized and may change when a lesion is found.

How VHL Treatment Works: Medicines and Procedures

For many VHL-related lesions, clinicians use a “watch-and-plan” approach. This means imaging them at planned intervals and intervening when growth, symptoms or location indicate that treatment is safer than continued observation. The timing is important: treating too early can expose a patient to avoidable procedures, while treating too late can risk permanent organ damage.

Surgery may be used for tumors that are causing symptoms, growing quickly or likely to compromise an organ. For kidney tumors, surgeons often aim for nephron-sparing surgery, which removes the tumor while retaining as much healthy kidney tissue as possible. Selected small kidney lesions may be treated with image-guided ablation, such as cryoablation or radiofrequency ablation.

Some tumors in the brain or spine, including hemangioblastomas, may need neurosurgical removal when they cause pressure, fluid buildup, pain, weakness or other neurological symptoms. Retinal lesions can sometimes be treated with laser therapy, cryotherapy or other ophthalmic approaches. Pheochromocytomas may require carefully planned adrenal surgery after appropriate medical preparation.

Belzutifan is a targeted VHL treatment drug that blocks hypoxia-inducible factor-2 alpha (HIF-2α), a pathway affected by the VHL gene change. In appropriately selected adults with VHL-associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors that do not require immediate surgery, it may reduce tumor size or help delay procedures. It is not suitable for every person or every VHL-related lesion, and it requires specialist monitoring.

Who May Be a Candidate for Belzutifan or a Procedure?

Candidacy is decided lesion by lesion. A person with VHL may have one small kidney tumor that can be monitored, a retinal lesion requiring eye treatment and another tumor for which a targeted medicine is being considered. The best option depends on anatomy, prior treatments, symptoms, kidney function, tumor behavior and personal priorities.

Belzutifan may be considered for eligible adults with certain VHL-associated tumors when immediate surgery is not necessary. Before treatment, clinicians review scans, blood tests, oxygen levels, other medicines and reproductive plans. Belzutifan can cause anemia and low oxygen levels, among other possible effects, so regular clinical and laboratory follow-up is important.

Procedures are generally considered when a tumor is threatening function or has features that make continued observation less appropriate. Decisions may also account for whether repeated surgery could affect kidney reserve, neurological function or vision. For complex cases, a specialist center can coordinate opinions from several relevant disciplines before a plan is finalized.

What Happens During Treatment and Recovery?

The steps depend on the type of treatment. Before a procedure, patients commonly have updated imaging, blood tests, anesthesia assessment and discussions about expected benefits, alternatives and possible complications. A surgical team may use open, laparoscopic or robotic techniques depending on the tumor location and complexity.

During kidney surgery, the surgeon removes or destroys the target lesion while seeking to preserve healthy tissue when possible. Brain or spinal surgery is planned around the precise location of the lesion and nearby nerves or blood vessels. Eye treatments are often outpatient procedures, although the expected visual recovery depends on the lesion and treatment used.

Recovery can range from a short return to normal activities after some image-guided or eye procedures to several weeks after major surgery. Follow-up scans remain necessary because VHL can lead to new lesions or growth in other areas. People taking belzutifan usually have scheduled visits and blood tests to assess treatment effect and side effects.

Potential benefits of treatment include preventing organ damage, relieving symptoms, controlling tumor growth and delaying more invasive procedures in selected situations. Risks vary by treatment and can include bleeding, infection, pain, reduced organ function, anesthesia-related complications, medication side effects or the need for further treatment. The treating team can explain the risks most relevant to an individual plan.

When Do People With VHL Develop Cancer?

People with VHL have an increased risk of certain cancers, particularly clear-cell renal cell carcinoma. Cancer risk is not the same for every person with VHL, and it does not mean that cancer is inevitable. Tumors and cysts can begin at different ages, and some VHL-related growths are noncancerous.

Kidney tumors associated with VHL may arise in adulthood, but surveillance often begins much earlier because earlier detection supports careful planning. The likelihood that a renal tumor needs treatment depends on its size, growth, appearance and location rather than age alone.

Other VHL-related tumors, such as central nervous system hemangioblastomas, retinal hemangioblastomas and many pancreatic cysts, are often benign but can still cause important health problems because of where they develop. Lifelong, individualized screening helps identify changes before they become more difficult to manage.

What Are the First Symptoms of Von Hippel Lindau?

Some people have no symptoms when VHL-related lesions are first found through routine screening or family testing. When symptoms occur, they depend on the organ involved. Early signs can include vision changes, headaches, balance problems, weakness, hearing changes, abdominal discomfort, high blood pressure or episodes of palpitations and sweating.

Symptoms may also be subtle. For example, a kidney tumor may not cause pain or visible blood in the urine early on, which is one reason regular imaging is important. A retinal lesion may initially affect only a small part of vision, while a brain or spinal lesion may cause gradually increasing headaches, neck pain, numbness or coordination difficulties.

These symptoms can have many causes and do not by themselves confirm VHL. Anyone with a personal or family history of VHL, or symptoms that are new, persistent or worsening, should discuss them with a qualified clinician rather than relying on symptoms alone.

How Much Does Belzutifan Typically Cost?

Belzutifan can be expensive, but the actual out-of-pocket cost varies widely by country, hospital system, insurance coverage, national reimbursement rules, pharmacy arrangements and eligibility for assistance programs. A single “typical” cost would therefore not be accurate or useful for all patients.

Before starting treatment, patients can ask the prescribing team, insurer or hospital financial counseling service about coverage, prior authorization requirements, monitoring costs and available support options. Cost discussions should happen alongside clinical discussions, so that financial considerations can be addressed without delaying necessary care.

It is important not to stop, start or substitute a prescribed VHL treatment drug because of cost concerns without speaking to the treating team. They may be able to clarify coverage pathways or discuss clinically appropriate alternatives.

What Is the Life Expectancy With VHL Syndrome?

Life expectancy with VHL syndrome varies considerably. It depends on the specific VHL-related tumors a person develops, how early they are detected, access to expert surveillance and treatment, and the effect of complications on vital organs. It is not possible to predict an individual outlook from the diagnosis alone.

Modern surveillance, organ-preserving surgery, targeted treatments and coordinated specialist care have improved the ability to detect and manage VHL-related tumors earlier. Many people with VHL lead active lives while attending regular screening appointments and receiving treatment only when needed.

A clinician who knows the person’s genetic findings, imaging history and current health can give the most meaningful discussion of prognosis. Emotional support, genetic counseling and practical planning can also be valuable parts of long-term care.

When to Seek Medical Care

People with known VHL should contact their care team promptly for new or worsening headaches, vomiting, balance problems, weakness, numbness, sudden vision changes, new hearing loss, severe abdominal or back pain, blood in the urine, or episodes of severe palpitations, sweating and high blood pressure. These symptoms do not always indicate a serious complication, but they deserve timely assessment.

Urgent medical evaluation is appropriate for sudden neurological symptoms, sudden or major vision loss, severe headache with confusion, chest pain, fainting, severe shortness of breath, or symptoms of a stroke. People with a close relative diagnosed with VHL should also ask a doctor or genetic counselor about testing and surveillance.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis, surveillance and treatment planning for international patients with VHL. Ongoing care should remain coordinated with qualified specialists familiar with the person’s complete medical history.

Frequently asked questions

Is there a cure for VHL syndrome?

There is currently no treatment that removes the inherited VHL gene change from the body. However, surveillance, medicines and procedures can manage many VHL-related tumors and reduce the risk of complications. Care is tailored throughout life as new findings may appear.

Does everyone with VHL need surgery?

No. Many small or stable lesions can be monitored with scheduled imaging and examinations. Surgery or another intervention is considered when a lesion is growing, causing symptoms or likely to affect organ function.

Can belzutifan replace surgery for VHL?

Belzutifan may help selected adults with certain VHL-related tumors and may delay or reduce the need for some procedures. It does not replace surgery in every situation, particularly when a tumor needs immediate local treatment. A specialist team determines whether medication, a procedure or surveillance is most appropriate.

How often are VHL scans needed?

The schedule differs according to age, genetic findings, previous tumors and current imaging results. Some examinations are done annually, while others may be more frequent when a lesion is being monitored closely. The treating team should provide a personalized surveillance calendar.

Can VHL be passed to children?

VHL is commonly inherited in an autosomal dominant pattern, meaning a person with the condition may pass the altered gene to each child. Genetic counseling can explain inheritance, testing options and implications for relatives. Family members should not assume their status without appropriate counseling and testing.

What should a person bring to a VHL specialist appointment?

It is helpful to bring prior MRI, CT and eye examination reports, imaging discs when available, genetic test reports, pathology reports, medication lists and a family history of tumors. Recording symptoms and their timing can also help the team assess whether a lesion may be causing them. Keeping records in one place supports long-term coordinated care.

References

• National Cancer Institute
• GeneReviews
• U.S. Food and Drug Administration
• National Organization for Rare Disorders
• European Society for Medical Oncology

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.